BCDA
Price
$1.04
Change
+$0.02 (+1.96%)
Updated
Oct 2 closing price
Capitalization
15.74M
40 days until earnings call
Intraday BUY SELL Signals
KOD
Price
$94.45
Change
-$4.01 (-4.07%)
Updated
Oct 2 closing price
Capitalization
5.65B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCDA vs KOD

BCDA vs KOD Comparison Chart in %
View a ticker or compare two or three
VS
BCDA vs. KOD commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a Hold and KOD is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BCDA vs KOD: Fundamental Ratings
BCDA
KOD
OUTLOOK RATING
1..100
8947
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
7634
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCDA's Valuation (80) in the null industry is in the same range as KOD (85) in the Biotechnology industry. This means that BCDA’s stock grew similarly to KOD’s over the last 12 months.

KOD's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that KOD’s stock grew similarly to BCDA’s over the last 12 months.

KOD's SMR Rating (100) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that KOD’s stock grew similarly to BCDA’s over the last 12 months.

KOD's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for BCDA (76) in the null industry. This means that KOD’s stock grew somewhat faster than BCDA’s over the last 12 months.

KOD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCDA (100) in the null industry. This means that KOD’s stock grew similarly to BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDAKOD
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
76%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (BCDA: $1.04 vs. KOD: $94.45)
Brand notoriety: BCDA and KOD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 21% vs. KOD: 156%
Market capitalization -- BCDA: $15.74M vs. KOD: $5.65B
BCDA [@Biotechnology] is valued at $15.74M. KOD’s [@Biotechnology] market capitalization is $5.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green while KOD’s FA Score has 0 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • KOD’s FA Score: 0 green, 5 red.
According to our system of comparison, KOD is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 4 TA indicator(s) are bullish while KOD’s TA Score has 5 bullish TA indicator(s).

  • BCDA’s TA Score: 4 bullish, 5 bearish.
  • KOD’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, KOD is a better buy in the short-term than BCDA.

Price Growth

BCDA (@Biotechnology) experienced а -0.95% price change this week, while KOD (@Biotechnology) price change was +191.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

BCDA is expected to report earnings on Nov 11, 2026.

KOD is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BCDA
Daily Signal:
Gain/Loss:
KOD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DMB9.480.11
+1.17%
BNY Mellon Municipal
TOPT35.210.32
+0.92%
iShares Top 20 U.S. Stocks ETF (TOPT)
ABCS33.550.14
+0.41%
Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)
XRMI17.320.06
+0.35%
Global X S&P 500 Risk Managed Income ETF (XRMI)
GBTC65.11-0.33
-0.50%
Grayscale Bitcoin Trust ETF (GBTC)

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been loosely correlated with XRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BCDA jumps, then XRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
+0.99%
XRTX - BCDA
43%
Loosely correlated
+2.37%
MDGL - BCDA
29%
Poorly correlated
-0.84%
INO - BCDA
28%
Poorly correlated
-0.82%
KOD - BCDA
28%
Poorly correlated
+3.86%
AUPH - BCDA
27%
Poorly correlated
-1.51%
More